CDK4/6 INHIBITION IMPROVES SURVIVAL IN ER+, HER2- BREAST CANCER

被引：0
|
作者：
不详
机构：
来源：
CANCER DISCOVERY | 2015年 / 5卷 / 02期
关键词：
D O I：
10.1158/2159-8290.CD-RW2015-001
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：107 / 107
页数：1
相关论文
共 50 条
  • [21] Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer
    Mai, Nicholas
    dos Anjos, Carlos H.
    Razavi, Pedram
    Safonov, Anton
    Patil, Sujata
    Chen, Yuan
    Drago, Joshua Z.
    Modi, Shanu
    Bromberg, Jacqueline F.
    Dang, Chau T.
    Liu, Dazhi
    Norton, Larry
    Robson, Mark
    Chandarlapaty, Sarat
    Jhaveri, Komal
    NPJ BREAST CANCER, 2024, 10 (01)
  • [22] Molecular determinants of resistance to CDK4/6 inhibition in ER plus breast cancer
    Luo, F.
    Cowley, G.
    Garraway, L.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S76 - S76
  • [23] The Role of CDK4/6 Inhibition in Breast Cancer
    Murphy, Conleth G.
    Dickler, Maura N.
    ONCOLOGIST, 2015, 20 (05): : 483 - U49
  • [24] Glucose Metabolic Reprogramming of ER+ Breast Cancer in Acquired Resistance to the CDK4/6 Inhibitor Palbociclib
    Lorito, Nicla
    Bacci, Marina
    Smiriglia, Alfredo
    Mannelli, Michele
    Parri, Matteo
    Comito, Giuseppina
    Ippolito, Luigi
    Giannoni, Elisa
    Bonechi, Martina
    Benelli, Matteo
    Migliaccio, Ilenia
    Malorni, Luca
    Chiarugi, Paola
    Morandi, Andrea
    CELLS, 2020, 9 (03)
  • [25] CDK4/6 inhibition in luminal breast cancer
    Gampenrieder S.P.
    Rinnerthaler G.
    Greil R.
    memo - Magazine of European Medical Oncology, 2016, 9 (2) : 76 - 81
  • [26] CDK4/6 inhibitors versus weekly paclitaxel for treatment of ER+/HER2-advanced breast cancer with impending or established visceral crisis
    Behrouzi, Roya
    Armstrong, Anne C.
    Howell, Sacha J.
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 202 (01) : 83 - 95
  • [27] A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2-breast cancer
    Servetto, Alberto
    Napolitano, Fabiana
    Angelis, Carmine De
    Placido, Pietro De
    Giuliano, Mario
    Arpino, Grazia
    Placido, Sabino De
    Bianco, Roberto
    Formisano, Luigi
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 157
  • [28] Genomic predictors of rapid progression to first line endocrine and CDK4/6 inhibitor combination therapy in patients with estrogen receptor positive (ER+) HER-2 negative (HER2-) advanced breast cancer (ABC)
    Velimirovic, Marko
    Gerratana, Lorenzo
    Davis, Andrew A.
    Hensing, Whitney L.
    Clifton, Katherine
    Shah, Ami N.
    D'Amico, Paolo
    Dai, Charles S.
    Denault, Elyssa N.
    Ma, Cynthia X.
    Wander, Seth A.
    Juric, Dejan
    Cristofanilli, Massimo
    Chabner, Bruce A.
    Bardia, Aditya
    CANCER RESEARCH, 2022, 82 (04)
  • [29] Mechanistic exploration of combined CDK4/6 and ER inhibition in ER-positive breast cancer
    Lee, Nathan V.
    Yuan, Jing
    Eisele, Koleen
    Cao, Joan Q.
    Painter, Cory L.
    Chionis, John
    Liu, Chaoting
    Shields, David J.
    Kan, Julie L. C.
    Arndt, Kim
    VanArsdale, Todd
    CANCER RESEARCH, 2014, 74 (19)
  • [30] Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives
    Iorfida, Monica
    Mazza, Manuelita
    Munzone, Elisabetta
    BREAST CANCER-TARGETS AND THERAPY, 2020, 12 : 45 - 56
12345